短程放化疗后化疗全程新辅助治疗用于潜在可切除胃癌患者的1期试验
这项1期试验评估了术前短程放化疗作为全程新辅助治疗一部分用于潜在可切除胃或胃食管腺癌患者的安全性和毒性。2021年3月至2022年12月入组24例患者,接受30 Gy/10次放化疗后全身治疗2个月再手术,所有患者完成放化疗,3级淋巴细胞减少7例(29%),中位随访28个月,中位总生存未达到,1年和3年总生存率分别为96%和85%。
要点
- 24例潜在可切除胃或胃食管腺癌患者接受短程放化疗(30 Gy/10次)序贯化疗2个月后手术。
- 放化疗相关毒性包括3级淋巴细胞减少7例(29%)、4级淋巴细胞减少1例(4%)、3级贫血1例(4%)。
- R0切除率95%,2例病理完全缓解,另有5例存活肿瘤≤1%,1年和3年总生存率分别为96%和85%。
核心结论
- 短程放化疗可作为计划性全程新辅助治疗的一部分安全用于潜在可切除胃或胃食管腺癌患者。
- 治疗完成率、病理缓解和总生存方面的良好结果支持进一步研究全程新辅助治疗用于胃癌。
研究设计与样本
- 1期试验,2021年3月至2022年12月入组24例潜在可切除胃或胃食管腺癌患者。
- 患者接受30 Gy/10次放化疗(同步卡培他滨或5-氟尿嘧啶),随后全身治疗2个月,再手术。
- 主要终点为放化疗安全性;次要终点为病理完全缓解、围手术期并发症和总生存。
主要发现
- 24例中10例(42%)有出血,3例(13%)有胃出口梗阻,2例(8%)有肝硬化,12例(50%)有临床淋巴结受累。
- 20例(83%)为低分化肿瘤,13例(54%)有印戒细胞组织学。
- 所有患者完成放化疗;放化疗相关毒性包括3级淋巴细胞减少7例(29%)、4级淋巴细胞减少1例(4%)、3级贫血1例(4%)。
- 放化疗后22例(92%)接受化疗,1例(4%)微卫星不稳定高肿瘤接受免疫治疗,1例(4%)未接受全身治疗直接切除。
- 所有患者尝试切除,20例(83%)行胃切除术,R0切除率95%;2例病理完全缓解,另有5例存活肿瘤≤1%。
临床怎么用
- 作者认为短程放化疗可作为计划性全程新辅助治疗的一部分安全用于潜在可切除胃或胃食管腺癌患者。
- 作者认为治疗完成率、病理缓解和总生存方面的良好结果支持进一步研究全程新辅助治疗用于胃癌。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The purpose of this phase 1 trial was to evaluate the safety and toxicity of preoperative short-course chemoradiotherapy (CRT) as part of total neoadjuvant therapy (TNT) for patients with potentially resectable gastric or gastroesophageal adenocarcinoma. METHODS AND MATERIALS: Patients were enrolled between March 2021 and December 2022 and received CRT (30 Gy radiation in 10 fractions with concurrent capecitabine or 5-fluorouracil), then received systemic therapy for 2 months, and then underwent surgery. The primary endpoint was CRT safety; secondary endpoints were pathologic complete response, perioperative complications, and overall survival (OS). RESULTS: Of the 24 patients enrolled in the trial, 10 (42%) had bleeding, 3 (13%) had gastric outlet obstruction, and 2 (8%) had cirrhosis. Twelve patients (50%) had clinical nodal involvement. Twenty patients (83%) had poorly differentiated tumors, and 13 (54%) had signet ring cell histology. All patients completed CRT. CRT treatment-related toxic effects included grade 3 lymphopenia in 7 patients (29%), grade 4 lymphopenia in 1 (4%), and grade 3 anemia in 1 (4%). After CRT, 22 patients (92%) received chemotherapy, 1 patient (4%) with a microsatellite instability-high tumor received immunotherapy, and 1 patient (4%) underwent resection without systemic therapy. All patients underwent attempted resection, and gastrectomy was performed in 20 (83%). The R0 resection rate was 95%. Two patients had pathologic complete response, and an additional 5 had ≤1% viable tumor. Three patients had surgical complications [grade 1 in 1 patient (4%), grade 3b in 1 (4%), and grade 4a in 1 (4%)]; no patients died within 90 days. The median follow-up time was 28 months, and median OS was not reached. The 1- and 3-year OS rates were 96% and 85%, respectively. CONCLUSION: Short-course CRT may be safely used as part of planned TNT for patients with potentially resectable gastric or gastroesophageal adenocarcinoma. The promising rates of treatment completion, pathologic response, and OS support further research of TNT for gastric cancer.
引用
- Badgwell B, Ikoma N, Murphy MB, et al. Phase 1 Trial of Total Neoadjuvant Therapy With Short-Course Chemoradiotherapy Followed by Chemotherapy for Patients With Potentially Resectable Gastric Cancer. Int J Radiat Oncol Biol Phys. 2024. PMID: 39237045. doi:10.1016/j.ijrobp.2024.08.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。